Exelixis Inc 2022 SR
The report marks Exelixis' inaugural sustainability disclosure, detailing the company's transition into a global multi-product oncology entity. Key highlights include the launch of the 'Inclusiveness Initiative' to diversify clinical trials and the achievement of a 100% carbon-neutral energy footprint for its new Alameda facility. The company reports that no patient prescribed its medicines goes without treatment for financial reasons through its EASE programs. Additionally, Exelixis achieved 100% employee participation in its first inclusion survey and maintains a workforce where 52% are women.
Company: Exelixis Inc
Sector: Health Care
Country: United States
Year: 2022
Type: SR
Pages: 56
Back to company
Exelixis Inc
Corporate Values And Sustainability Report
The report marks Exelixis' inaugural sustainability disclosure, detailing the company's transition into a global multi-product oncology entity. Key highlights include the launch of the 'Inclusiveness Initiative' to diversify clinical trials and the achievement of a 100% carbon-neutral energy footprint for its new Alameda facility. The company reports that no patient prescribed its medicines goes without treatment for financial reasons through its EASE programs. Additionally, Exelixis achieved 100% employee participation in its first inclusion survey and maintains a workforce where 52% are women.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2021 - Oct 1, 2022
Fiscal Year
2022
Published
Oct 1, 2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Total Waste
Women on Board
Women in Management
Employees